Cohance Lifesciences Reports Q1 FY27 Unaudited Financial Results
Cohance Lifesciences reported unaudited Q1 FY27 results. Standalone income was ₹359.89 crore, with net profit at ₹1.41 crore. Consolidated income was ₹422.26 crore, with net profit at ₹46.40 crore. The Board approved the results on August 4, 2026.
The financial results show a notable decline in performance, which could impact investor sentiment and stock price. However, the company is still profitable on a consolidated basis.
The company reported a significant decrease in both standalone and consolidated total income and net profit compared to the same quarter last year.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a standalone total income from operations of ₹359.89 crore, a decrease from ₹483.58 crore in the same quarter last year. Standalone net profit after tax was ₹1.41 crore, down from ₹52.57 crore year-on-year.
On a consolidated basis, total income from operations stood at ₹422.26 crore, a decrease from ₹549.31 crore in the corresponding quarter of the previous fiscal. Consolidated net profit after tax was ₹46.40 crore, compared to ₹150.12 crore in the prior year's quarter. The company's equity share capital remained stable at ₹38.26 crore. Basic EPS on a standalone basis was ₹0.04, and diluted EPS was ₹0.04. Consolidated basic EPS was (₹0.63) and diluted EPS was (₹0.65).
The detailed financial results were reviewed by the Audit Committee and approved by the Board of Directors on August 4, 2026. The full financial results are available on the company's website and the websites of the stock exchanges.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.